Plumbagin

Plumbagin is a naphthoquinone compound extracted from plants like Plumbago zeylanica that demonstrates anticancer properties through multiple cellular pathways. Research shows it may inhibit tumor growth by inducing apoptosis and blocking angiogenesis in cancer cells.

Origin & History

Plumbagin is a naphthoquinone compound isolated from the root of Plumbago zeylanica L., a medicinal plant used in traditional healing systems. It is extracted from plant material and has been formulated in various delivery systems, including sesame oil-based preparations for research studies.

Historical & Cultural Context

Plumbago zeylanica L. is identified as a medicinal plant from which plumbagin is isolated, with established use in traditional healing practices. However, specific traditional medicine systems and historical applications are not detailed in the available research.

Health Benefits

• May inhibit prostate cancer growth - mouse studies showed 50% tumor regression at 1 mg/kg combined with castration (preliminary evidence only)
• Potential pancreatic cancer suppression - animal studies demonstrated significant tumor volume reduction of 55% at 2 mg/kg (preliminary evidence only)
• Possible esophageal cancer cell inhibition - in vitro studies showed dose-dependent reduction in ESCC cell proliferation (preliminary evidence only)
• May target tongue cancer pathways - inhibited growth in patient-derived xenograft models via Akt/mTOR suppression (preliminary evidence only)
• Selective cancer cell targeting - showed selective apoptosis induction in cancer cells while sparing normal prostate epithelial cells (preliminary evidence only)

How It Works

Plumbagin exerts anticancer effects by generating reactive oxygen species (ROS) that trigger apoptosis in malignant cells while sparing normal tissue. It inhibits NF-κB signaling pathways, reduces VEGF expression to block angiogenesis, and modulates p53 tumor suppressor protein activity. The compound also interferes with topoisomerase II enzyme function, disrupting DNA replication in rapidly dividing cancer cells.

Scientific Research

No human clinical trials or randomized controlled trials have been conducted with plumbagin. All available evidence comes from preclinical studies using cell cultures and animal models, including prostate cancer mouse studies showing 90% tumor reduction at 2 mg/kg intraperitoneal administration and pancreatic cancer studies in SCID mice demonstrating significant tumor inhibition.

Clinical Summary

Current evidence for plumbagin comes primarily from preclinical animal studies rather than human trials. Mouse studies showed 50% prostate tumor regression at 1 mg/kg when combined with castration therapy. Separate animal research demonstrated 55% pancreatic tumor volume reduction at 2 mg/kg dosing. No completed human clinical trials have established safety profiles or therapeutic dosing ranges for cancer treatment applications.

Nutritional Profile

Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) is a naturally occurring naphthoquinone compound, not a food or nutrient, so it does not possess a conventional nutritional profile with macronutrients, vitamins, or minerals. Key biochemical and compositional details include: • Molecular formula: C₁₁H₈O₃; Molecular weight: 188.18 g/mol • Found naturally in plants of the family Plumbaginaceae (especially Plumbago zeylanica root bark, ~0.5–1.0% dry weight), Droseraceae (Drosera species, sundews), Nepenthaceae, and Diospyros species • Classification: 1,4-naphthoquinone derivative; lipophilic bioactive secondary plant metabolite • Key functional groups: hydroxyl group at C-5, methyl group at C-2, and quinone carbonyl groups at C-1 and C-4 — these are critical for its redox-cycling activity and generation of reactive oxygen species (ROS) • Bioavailability notes: Plumbagin is lipophilic (LogP ~1.6–2.0), allowing reasonable cell membrane permeability; however, oral bioavailability in animal models is limited (estimated ~20–30% in rodent pharmacokinetic studies) due to rapid Phase I and Phase II hepatic metabolism (glucuronidation and reduction of the quinone moiety); plasma half-life in rats is approximately 2–4 hours after intraperitoneal administration at 2 mg/kg • Typical experimental dosages in preclinical research: 1–4 mg/kg body weight in animal models (intraperitoneal or oral gavage); in vitro IC₅₀ values range from 1–10 µM depending on cell line • No dietary reference intakes, recommended daily values, or macro/micronutrient contributions exist as plumbagin is not consumed as a food; it contains no appreciable protein, carbohydrate, fat, fiber, vitamins, or minerals • Primary bioactive mechanism: acts as a pro-oxidant via intracellular redox cycling generating superoxide anion (O₂⁻) and hydrogen peroxide (H₂O₂), inhibits NF-κB signaling, modulates STAT3 and PI3K/Akt/mTOR pathways, and may inhibit topoisomerase II • Toxicity concern: narrow therapeutic index — LD₅₀ in mice is approximately 8–16 mg/kg (intraperitoneal), making it cytotoxic at doses only modestly above pharmacologically active concentrations; hepatotoxicity and reproductive toxicity observed in animal studies at higher doses

Preparation & Dosage

Animal studies used: Oral (sesame oil formulation): 1 mg/kg body weight; Intraperitoneal injection: 2 mg/kg body weight, 5 days per week. In vitro studies used 5-15 μM concentrations. No human dosages have been established. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Sesame oil (for absorption), Curcumin, Green tea extract, Quercetin, Resveratrol

Safety & Interactions

Plumbagin safety data in humans remains limited due to lack of clinical trials. Animal studies suggest potential hepatotoxicity and nephrotoxicity at higher doses, requiring careful monitoring. The compound may interact with chemotherapy drugs by enhancing their cytotoxic effects, potentially increasing side effects. Pregnancy and breastfeeding safety has not been established, and use should be avoided during these periods.